RxDoctor Payments Data

Christopher Devine, MD

Ophthalmology · Cincinnati, OHNPI 1205838562

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $2,081 of the $2,396 with a category attached, or 86.8%. 12 manufacturers reported payments, led by Abiomed at 25.3% of the total.

$2,396in general payments, 2019–2025

Across 64 payments — averaging $37.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abiomed$605
  • AbbVie$385
  • Genentech USA, Inc.$306
  • Novartis$282
  • Alimera Sciences, Inc.$249
  • Astellas Pharma US Inc$162
  • plus $407 from 6 others
$620,986in research payments, 2019–2025

Across 112 payments — averaging $5544.51 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Roche TCRC, Inc.$295K
  • AstraZeneca$99K
  • Boehringer Ingelheim$70K
  • Regeneron$67K
  • Amgen$39K
  • Boehringer Ingelheim International GmbH$32K
  • plus $20K from 3 others

What the payments were for

  • Travel & lodging$31513%
  • Food & beverage$2,08187%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,396 in reported general payments places this provider in the 65th percentile of 640 ophthalmology providers in Ohio.

See all ophthalmology providers in Ohio

Medicare billing

Part B allowed, 2024
$1,383,656
Medicare patients
582
Services billed
11,367

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Prednisolone Acetate141$3,520
Ofloxacin140$1,305
Latanoprost25$387

Paid to pharmacies, not to this prescriber.

Other ophthalmology in Cincinnati

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →